In March of 2019, the S(+) stereoisomer of ketamine identified as esketamine was approved via the FDA as a quick-acting antidepressant. It relieves the signs or symptoms of melancholy within just 4 hrs of use and these effects can previous for so long as many weeks.“We at Ketamine Infusion Facilities experience our professional staff supply the h… Read More